Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab with concurrent chemoradiotherapy as adjuvant therapy after radical surgery for cervical cancer
ChiCTR2400085618Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival (PFS). Started Jun 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400085618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085618.